Default company panoramic image

Altrika Ltd.

An in-revenue woundcare company with two patent-protected, cell-based products to treat burns and other hard-to-heal wounds.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency GBP
  • Founded December 2008
  • Employees 5
  • Website

Company Summary

Altrika manufactures and markets two cultured cell-based products to treat burns and other hard-to-heal wounds.There is a shortage of effective treatments for severe wounds and cell therapy provides accelerated wound closure and improved skin quality. Current customers are UK NHS burn centre hospitals and we plan to roll the products out on large, growing global markets, again targetting specialist burns hospitals and other wound care centres.


  • Default avatar
    Richard Andrew Snell

    Richard is responsible for Altrika’s business development activities since the company was founded in 2008, including developing the roll-out strategy for Altrika’s skin products, and securing a range of commercial and grant-funded R&D programmes.Before this, he held senior positions in the MedTech Division of Cambridge Consultants, and worked in various roles for Shell. He studied Engineering at Cambridge and holds a Diploma in Finance from ACCA

  • Default avatar
    David Haddow

    David is Altrika’s Operations Director and is responsible for the development to market of its cell based therapies. He has experience in product development, scale-up, GMP manufacture and regulatory compliance at UK and European levels, project management and clinical evaluation. He is an assessor for the Human Tissue Authority (HTA) and the Designated Individual for both the HTA and MHRA. He has a PhD from Sheffield and a MEng from Oxford.


  • Default avatar
    Bond Pearce
    Default avatar

Previous Investors

  • Default avatar
    Ilika plc